243 related articles for article (PubMed ID: 16675705)
1. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
Kelly DF; Snape MD; Clutterbuck EA; Green S; Snowden C; Diggle L; Yu LM; Borkowski A; Moxon ER; Pollard AJ
Blood; 2006 Oct; 108(8):2642-7. PubMed ID: 16675705
[TBL] [Abstract][Full Text] [Related]
2. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
[TBL] [Abstract][Full Text] [Related]
3. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
4. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
5. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
Riddell A; Buttery JP; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
Vaccine; 2007 May; 25(19):3906-12. PubMed ID: 17368663
[TBL] [Abstract][Full Text] [Related]
6. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
[TBL] [Abstract][Full Text] [Related]
7. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
[TBL] [Abstract][Full Text] [Related]
8. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.
Blanchard Rohner G; Snape MD; Kelly DF; John T; Morant A; Yu LM; Borkowski A; Ceddia F; Borrow R; Siegrist CA; Pollard AJ
J Immunol; 2008 Feb; 180(4):2165-73. PubMed ID: 18250423
[TBL] [Abstract][Full Text] [Related]
9. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
10. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
11. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults.
Lakshman R; Burkinshaw R; Choo S; Finn A
Vaccine; 2002 Nov; 20(31-32):3778-82. PubMed ID: 12399209
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.
Wing JB; Smart L; Borrow R; Findlow J; Findlow H; Heath AW; Read RC
Clin Infect Dis; 2011 Jun; 52(11):1317-23. PubMed ID: 21596673
[TBL] [Abstract][Full Text] [Related]
13. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
14. Polysaccharide-specific memory B cells generated by conjugate vaccines in humans conform to the CD27+IgG+ isotype-switched memory B Cell phenotype and require contact-dependent signals from bystander T cells activated by bacterial proteins to differentiate into plasma cells.
Clarke ET; Williams NA; Findlow J; Borrow R; Heyderman RS; Finn A
J Immunol; 2013 Dec; 191(12):6071-83. PubMed ID: 24227777
[TBL] [Abstract][Full Text] [Related]
15. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.
Harris SL; Finn A; Granoff DM
Infect Immun; 2003 Jun; 71(6):3402-8. PubMed ID: 12761124
[TBL] [Abstract][Full Text] [Related]
16. Meningococcal serogroup C polysaccharide specific memory B cells, directly enumerated by labeled polysaccharide, are not affected by age at vaccination.
Henneken M; Burdin N; Thoroddsen E; Sigurdardottir ST; Trannoy E; Jonsdottir I
Vaccine; 2010 Feb; 28(9):2097-103. PubMed ID: 20056181
[TBL] [Abstract][Full Text] [Related]
17. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.
Prinz DM; Smithson SL; Kieber-Emmons T; Westerink MA
Immunology; 2003 Oct; 110(2):242-9. PubMed ID: 14511238
[TBL] [Abstract][Full Text] [Related]
18. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.
Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D
Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
